Written by: Xu Yi'an
Last update date: 2021-02-27 16:50
The first batch of 1 million doses of the Comirnaty vaccine, jointly developed by Fosun Pharma and BioNTech, will be delivered to Hong Kong in two flights from Germany.
585,000 doses arrived in Hong Kong on February 27, and the first remaining doses arrived in early March.
At the same time, the American pharmaceutical companies Pfizer and BioNTech, which are developing vaccines, are planning to make a new attempt on the BNT162 vaccine, i.e. Fubitel.
Fierce Pharmaceutical Information website (fiercepharma.com) reported on February 25 that Pfizer and BioNTech started testing whether the third dose of the vaccine is effective against the novel coronavirus pneumonia (COVID-19) variant virus.
Pfizer CEO Albert Bourla once told NBC that he believes that the third dose of vaccine "will increase the antibody response by 10 to 20 times.
Liu Zexing: It is difficult for Kexing and Fubitai to compare figures alone. The most important thing is that they meet the WHO standard.
New Crown Vaccine｜Fobitai only delivers 585,000 doses of vaccine to Hong Kong today, open appointment for vaccination next week
New crown pneumonia | 1 million doses of Fubitai vaccine expected to be vaccinated in early March. More than 20 vaccination centers in Hong Kong
The test will study 2 groups of people, 18 to 55 years old, and 65 to 85 years old.
They all participated in the first phase of clinical testing in May 2020.
They will receive a third dose, just like the 2 doses they received 6 to 12 months ago.
BioNTech/Fosun Vaccine New Coronary Pneumonia New Coronary Vaccine